The Critical Path Institute

The Critical Path Institute, doing business as C-Path, is a tax-exempt nonprofit organization headquartered in Tucson, Arizona, that delivers drug development tools, clinical outcome assessment frameworks, and biomarker qualification research to the Food and Drug Administration and affiliated federal agencies as a prime recipient on federal grants and contracts. C-Path operates almost exclusively as a prime (97% of recent awards) and competes full-and-open without set-aside designations.

C-Path's federal footprint concentrates heavily with the Food and Drug Administration and its constituent centers. The FDA accounts for the overwhelming majority of recent activity—18 awards across multiple FDA entities—with the Center for Drug Evaluation and Research (CDER) emerging as the dominant customer. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response represents the secondary customer with one award valued at $202 thousand. The top customer by potential value, the FDA (11 awards), carries $14.5 million in combined potential value; this accounts for 100% of C-Path's documented potential-value concentration.

C-Path's capability portfolio centers on patient-reported outcome measures (PROs), clinical outcome assessments (COAs), and biomarker qualification for FDA regulatory science and drug development. Representative work includes a $3.376 million definitive contract awarded by the FDA in August 2024 for development of drug development tools for autosomal dominant tubulointerstitial kidney disease (ADTKD), combining clinical phenotyping data ingestion, biomarker landscape analysis, and patient identification for longitudinal measurement; a $4.418 million definitive contract from the FDA (awarded September 2022) to develop a standardized framework supporting FDA qualification of complex in vitro models for regulatory submissions; and ongoing cooperative agreements from CDER including $250 thousand (September 2025 through August 2026) for psychometric analyses qualifying the Pediatric Asthma Diary-Child (PAD-C) and Pediatric Asthma Diary-Observer (PAD-O) as clinical outcome assessment tools. C-Path also holds cooperative agreements addressing unmet measurement needs in multiple sclerosis (fatigue and physical function), chronic heart failure symptom assessment and activity monitoring, Alzheimer's disease functional capacity measurement, and irritable bowel syndrome symptom severity. Additional work spans biomarker qualification for drug-induced liver injury and skeletal muscle injury detection, drawing on studies with collaborating academic institutions such as the University of Michigan Hospital.

Activity shows concentration in recent years with seven awards in 2024, one in 2025, and one in 2026, following lower volume in 2022 and 2023. Four awards carrying combined potential value of $4.4 million face ultimate completion within the next twenty-four months and expose C-Path to recompete. SCI-reported invoicing on federal service contracts captured $1.1 million in FY2022, $1.2 million in FY2023, and $1.3 million in FY2024, scaling roughly 4 to 6 FTEs annually in those years. On federal services contracts, government-paid rates median around $107.93 per hour, with senior labor pricing through $128.30 per hour and junior rates starting at $80.62 per hour. Across SCI-reportable prime contracts, subcontractors perform approximately 10% of total contractor hours; Wake Forest University Health Sciences subcontracts on the ADTKD development contract for biobanking and biomarker analysis. C-Path also received a federal grant sub-award from The Johns Hopkins University in February 2024 related to observational medical outcomes research for pregnant women and early childhood populations.